Serum HE4 and serum clinical significance of CA125 in diagnosis of ovarian neoplasms transvaginal color Doppler ultrasound
ZHANG Dan1,LIU Yinglan2, and LIU Xuening1
1. Department of Ultrasonic, Heilongjiang Provincial Corps Hospital of Chinese People’s Armed Police Forces, Harbin 150076,China. 2. Department of Gynaecology and Obstetrics, First Affiliated Hospital of Harbin Medical University, Harbin 150010,China
Abstract：Objective To study significance of combined with ultrasound score and serum HE4, CA125 in differentiating malignant from benign ovarian tumor. Methods Senventy-eight cases of epithelial ovarian cancer (ovarian cancer group) and 102 cases of benign ovarian tumor (benign ovarian tumor group) measured the serum level of CA125, results are expressed as median (M) said. In 80 cases of normal people as control (control group). By making the receiver operating characteristic (ROC) curve, the area under the curve (AUC) to reflect the accuracy of diagnosis. At the same time, ultrasonic scoring system scores of the two groups of patients, ultrasound scoring system and different tumor markers combination were calculated on the sensitivity, specificity of diagnosis of ovarian cancer. Results The serum HE4 and CA125 in ovarian cancer is significantly higher than that in benign ovarian tumor group and normal control group, compared the differences were statistically significant (P<0.05); Compard ovarian benign tumor group and the normal control group, HE4 showed no statistically significant difference (P>0.05), CA125 show a significant difference(P<0.05). The specificity and sensitivity of HE4 were 94.3%, 96.1%; The specificity and sensitivity of CA125 were 87.4%, 94.2%. HE4 CA125, ultrasonic scoring system of combined detection of three kinds of sensitivity of 96.1%. Conclusions HE4 and CA125 in combination with ultrasonic scoring system for differential diagnosis of the highest sensitivity.
张丹,柳英兰,刘学宁. 超声评分系统结合血清附睾分泌蛋白4、CA125对卵巢肿瘤的诊断意义[J]. 武警医学, 2014, 25(12): 1242-1244.
ZHANG Dan,LIU Yinglan, and LIU Xuening. Serum HE4 and serum clinical significance of CA125 in diagnosis of ovarian neoplasms transvaginal color Doppler ultrasound. Med. J. Chin. Peop. Armed Poli. Forc., 2014, 25(12): 1242-1244.
Finkler N I,Benacerraf B I,Lavin P, et al.Comparison of serum CA125, clinical impression and ultrasound in the preoperative evaluation of ovarian masses[J].Obstet Gynecol,1988,72:659-663.
[1]
Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening [J]. Gynecol Onco, 2003, 88: 152-157.
[6]
Lerner J R,Timor I E,Fedeman A, et al.Transv -aginal ultrasonographic characterization of ovarian masseswith an inproved,werghted scoring system [J].Am J Obstet Gynecol,1994,170:81-87.
[2]
Cohen L S, Escobar P F, Scharm C, et al. Three dimension al power doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction [J] . Gynecol Onco, 2001, 84(2) : 352-353.
[7]
Weber G,Merz E,Bahlmann F, et al.A new so Nnomorphologic scoring- system (Mainz score)for the assessment of ovarian tumors using transvaginal ultrasonography[J].Ultraschall Med,1999,20(1):2-8.
[8]
Juan L.A newscoring systemto differentiate benign from nalignant adnexal masses[J].Am J Obstet Gynecol,2003,34(4):685-697.
[3]
Valentin L.Limited contribution of Doppler velocimetry to the differential diagnosis of extrauterine pelvic tumors[J].Obstet Gynecol,1994,83:425-433.
[9]
Karlsen N S, Karlsen M A, Hgdall C K,et al.HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review[J].Cancer Epidemiol Biomarkers Prev,2014,23(11):2285-2295.
Sasson A M,Timor I E,Antner A, et al.Transvaginal sonographic characterization of ovarian diseases: Evaluation of a new scoring system to predict malignancy[J].Obsetet Gynecol,1991,78:70-76.
[11]
Shah C A, Low e K A, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarker smesothelin, HE4, and CA125[J]. Cancer Epidemiol Biomarkers Prev, 2009,18(5):1365-1372.
[5]
Finkler N I,Benacerraf B I,Lavin P, et al.Comparison of serum CA125, clinical impression and ultrasound in the preoperative evaluation of ovarian masses[J].Obstet Gynecol,1988,72:659-663.
[6]
Lerner J R,Timor I E,Fedeman A, et al.Transv -aginal ultrasonographic characterization of ovarian masseswith an inproved,werghted scoring system [J].Am J Obstet Gynecol,1994,170:81-87.
[7]
Weber G,Merz E,Bahlmann F, et al.A new so Nnomorphologic scoring- system (Mainz score)for the assessment of ovarian tumors using transvaginal ultrasonography[J].Ultraschall Med,1999,20(1):2-8.
[8]
Juan L.A newscoring systemto differentiate benign from nalignant adnexal masses[J].Am J Obstet Gynecol,2003,34(4):685-697.
[9]
Karlsen N S, Karlsen M A, Hgdall C K,et al.HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review[J].Cancer Epidemiol Biomarkers Prev,2014,23(11):2285-2295.
Shah C A, Low e K A, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarker smesothelin, HE4, and CA125[J]. Cancer Epidemiol Biomarkers Prev, 2009,18(5):1365-1372.
2014, Vol. 25 
